Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Adam Daunton

Showing results (11-20 of 15) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 15 results.
American Journal of Clinical Dermatology|April 13, 2023
Chronic Telogen Effluvium: Is it a Distinct Condition? A Systematic ReviewAdam Daunton, Matthew Harries, Rodney Sinclair, et al.
Journal of Clinical Medicine|May 27, 2026
Misnomers in Dermatology and Other Medical Specialties-How to Deal with Science Fiction?Vera L Baumann Griss, Radina V Velikova, Peter Itin, et al.
The Australasian Journal of Dermatology|September 30, 2025
Systemic Treatment of Moderate to Severe Alopecia Areata in Adults: Updated Australian Expert Consensus StatementDaniella Kushnir-Grinbaum, Laita Bokhari, John Frewen, et al.
JAMA Oncology|January 23, 2016
Clinical Outcomes and Survival Following Treatment of Metastatic Castrate-Refractory Prostate Cancer With Docetaxel Alone or With Strontium-89, Zoledronic Acid, or Both: The TRAPEZE Randomized Clinical TrialNicholas D James, Sarah J Pirrie, Ann M Pope, et al.
BJU International|June 4, 2016
Cost-effectiveness of zoledronic acid and strontium-89 as bone protecting treatments in addition to chemotherapy in patients with metastatic castrate-refractory prostate cancer: results from the TRAPEZE trial (ISRCTN 12808747)Lazaros Andronis, Ilias Goranitis, Sarah Pirrie, et al.
Pageof 2

Showing results (11-20 of 15) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 15 results.
American Journal of Clinical Dermatology|April 13, 2023
Chronic Telogen Effluvium: Is it a Distinct Condition? A Systematic ReviewAdam Daunton, Matthew Harries, Rodney Sinclair, et al.
Journal of Clinical Medicine|May 27, 2026
Misnomers in Dermatology and Other Medical Specialties-How to Deal with Science Fiction?Vera L Baumann Griss, Radina V Velikova, Peter Itin, et al.
The Australasian Journal of Dermatology|September 30, 2025
Systemic Treatment of Moderate to Severe Alopecia Areata in Adults: Updated Australian Expert Consensus StatementDaniella Kushnir-Grinbaum, Laita Bokhari, John Frewen, et al.
JAMA Oncology|January 23, 2016
Clinical Outcomes and Survival Following Treatment of Metastatic Castrate-Refractory Prostate Cancer With Docetaxel Alone or With Strontium-89, Zoledronic Acid, or Both: The TRAPEZE Randomized Clinical TrialNicholas D James, Sarah J Pirrie, Ann M Pope, et al.
BJU International|June 4, 2016
Cost-effectiveness of zoledronic acid and strontium-89 as bone protecting treatments in addition to chemotherapy in patients with metastatic castrate-refractory prostate cancer: results from the TRAPEZE trial (ISRCTN 12808747)Lazaros Andronis, Ilias Goranitis, Sarah Pirrie, et al.
Pageof 2